Response to share price movement

4 February 2020

NMC Health plc

(the "Company" or "NMC")

Response to share price movement

NMC Health PLC ("NMC" or the "Company") notes the decline in the Company's share price yesterday and confirms that it knows of no specific reason for the fall. The independent review being undertaken by Freeh Group International Solutions LLC, announced on 17 January 2020, is proceeding. The Company's operations continue to perform strongly and the Company expects to report full-year 2019 results in-line with management's expectations.

Contacts

About NMC Health

NMC is one of the leading private healthcare operators in the Gulf Cooperation Council ("GCC") with an international network of multi-specialty inpatient and outpatient clinics and hospitals, specialized maternity and fertility clinics, and long-term care homes hospitals across nineteen countries. NMC also ranks as one of the top two in-vitro fertilisation operators globally. The NMC Health group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion programme since 2016, NMC has total capacity of 2,207 licensed beds across its network. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. The NMC Health group treated over 7.5 million patients in 2018. The NMC Health group is also a leading UAE supplier of products and consumables coming from healthcare related products. NMC reported revenues of US$2.1 billion for the year ended 31 December 2018.

In April 2012, NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index.